Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Dermatol Surg ; 46(7): 928-933, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-31584525

RESUMEN

BACKGROUND: Although there are multiple treatments for warts, wart management remains a challenge. Ozone therapy is an emerging treatment for infectious and noninfectious dermatological diseases. OBJECTIVE: To assess intralesional ozone gas safety and efficacy in multiple warts management. MATERIALS AND METHODS: Seventy-four adult patients with multiple common warts were included in this study. They were randomly assigned into 2 groups: first group comprised 44 patients treated with intralesional ozone gas, and the second group comprised 30 patients who received intralesional saline injection. In both groups, warts in all patients were directly injected weekly until complete clearance occurred or for a maximum of 10 treatment sessions. The subjects were followed for 6 months to record any recurrences. RESULTS: In the ozone group, 25 patients (56.8%) had a complete response with an excellent cosmetic outcome, 15 patients (34.1%) showed a partial response, and 4 patients (9.1%) had no response. More subjects responded to ozone than to saline (p < .001). Ozone therapy was associated with mild side effects, including pain at time of injection, numbness, and fatigue. CONCLUSION: Intralesional ozone is effective and safe for the treatment of multiple warts.


Asunto(s)
Ozono/administración & dosificación , Enfermedades de la Piel/tratamiento farmacológico , Verrugas/tratamiento farmacológico , Adolescente , Adulto , Femenino , Humanos , Inyecciones Intralesiones , Masculino , Persona de Mediana Edad , Inducción de Remisión , Enfermedades de la Piel/patología , Verrugas/patología , Adulto Joven
2.
J Cosmet Dermatol ; 19(4): 964-969, 2020 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-31436378

RESUMEN

BACKGROUND: The outcomes of most therapeutic modalities for recurrent aphthous ulcer (RAU) are still unsatisfactory. AIM: To evaluate lactic acid 5% mouth wash vs Kenalog in Orabase for treatment and prophylaxis of RAU. PATIENTS/METHODS: Forty cases with early-onset idiopathic RAU were enrolled in this study. Patients were divided into two equal groups; group A patients had used Kenalog in Orabase twice daily, and group B patients had used lactic acid 5% mouth wash 3 times daily. All patients had used the therapy for 1-2 weeks according to patients' clinical response that was evaluated according to oral clinical manifestations index (OCMI); before therapy, during course of treatments and in follow-up visits. RESULTS: At the ends of both first and second weeks, from beginning of therapy, OCMI was reduced more in group B patients than in group A with statistically significant results. These results revealed that group B achieved more reduction in the size, pain, and healing time of RAU. During the follow-up period, group A showed 40% recurrence rate while group B showed 5% only. CONCLUSIONS: Lactic acid 5% mouth wash is natural, safe, and effective so it is better alternative to corticosteroids for treatment and prophylaxis of RAU without any side effects.


Asunto(s)
Carboximetilcelulosa de Sodio/análogos & derivados , Ácido Láctico/administración & dosificación , Antisépticos Bucales/administración & dosificación , Estomatitis Aftosa/tratamiento farmacológico , Triamcinolona Acetonida/administración & dosificación , Adulto , Carboximetilcelulosa de Sodio/administración & dosificación , Carboximetilcelulosa de Sodio/efectos adversos , Esquema de Medicación , Combinación de Medicamentos , Femenino , Estudios de Seguimiento , Humanos , Ácido Láctico/efectos adversos , Masculino , Persona de Mediana Edad , Antisépticos Bucales/efectos adversos , Recurrencia , Índice de Severidad de la Enfermedad , Estomatitis Aftosa/diagnóstico , Estomatitis Aftosa/prevención & control , Resultado del Tratamiento , Triamcinolona Acetonida/efectos adversos , Adulto Joven
3.
Dermatol Ther ; 32(5): e13051, 2019 09.
Artículo en Inglés | MEDLINE | ID: mdl-31381231

RESUMEN

Psoriasis is a common inflammatory skin disorder with complex pathomechanisms. Methotrexate (MTX) is an antiproliferative and immunomodulating agent that control psoriasis. The aim of this study is to compare the efficacy of MTX and tolerability to MTX by oral route versus subcutaneous (SC) route. Twenty-eight cases were divided into two equal groups: Group I received a weekly dose of oral MTX and Group II received a weekly dose of SC MTX for 12 weeks. The starting dose was 7.5-10 mg and increased gradually by 2.5 mg every month till reaching 12.5-15 mg/week. Patients' clinical responses were evaluated according to Psoriasis Area and Severity Index (PASI) score. Results suggest that Group I patients showed reduction in PASI score of mean ± SD from 19 ± 7.4 before treatment to 11.2 ± 6.29 after treatment while Group II patients showed reduction from 23.4 ± 14.7 before treatment to 2.55 ± 2.6 after treatment with highly statistically significant difference between both groups. Clinical improvement was complete in 7.1% of Group I versus 57.1% of Group II. In conclusion, SC MTX has higher efficacy with lesser adverse effects and lower relapse rate when compared to oral form given by the same dose during the same duration.


Asunto(s)
Inmunosupresores/administración & dosificación , Metotrexato/administración & dosificación , Psoriasis/tratamiento farmacológico , Psoriasis/prevención & control , Administración Oral , Estudios de Cohortes , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Femenino , Humanos , Inyecciones Subcutáneas , Masculino , Pronóstico , Medición de Riesgo , Índice de Severidad de la Enfermedad , Estadísticas no Paramétricas , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA